Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule
The notice from Nasdaq indicates that the Company is in compliance with the Nasdaq Capital Market's listing requirements and the Company's common stock will continue to be listed and traded on Nasdaq.
Robert Hayes, CEO of Sharps Technology, commented: 'Maintaining our listing on Nasdaq is of critical importance, and we are pleased to have met the exchange's requirements to continue trading. Sharps is at a pivotal inflection point in its history as we transition from the pre-revenue qualification phase to revenue-generating commercial operations. Over the past month, we received our first purchase orders for SecureGard and SoloGard, and we will soon begin shipping product from our Hungary-based manufacturing facility. As we move forward with commercial operations, we look forward to providing regular updates to our shareholders.'
About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit www.sharpstechnology.com.
FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@sharpstechnology.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The Food and Drug Administration (FDA) approved ORLYNVAH™ for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH™ is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies. Sixty percent of women experience a urinary tract infection in their lifetime and 44% experience three or more episodes annually. It is the most common outpatient infection in women in the United States, and resistance continues to increase. According to a 2024 U.S. study in approximately 150,000 patients with uncomplicated UTIs: 57% of initial infections were resistant to at least one antibiotic class; and 13% were resistant to three or more. Without new, safe and effective oral therapies, resistant uUTIs are expected to inflate healthcare costs and may lead to poor patient outcomes in the U.S., including the need for additional courses of therapy, emergency room visits or hospitalizations, all of which underscore the urgent need for innovation in this space. 'The availability of ORLYNVAH™ is tremendous news for clinicians and patients alike,' said Marjorie Golden, MD, FIDSA, Site Chief, Infectious Disease, St. Raphael Campus Yale New Haven Hospital. 'The launch of ORLYNVAH™ provides a new treatment option with impressive efficacy data to treat appropriate adult women suffering from difficult-to-treat uUTIs.' Dr. Golden added, 'For patients who currently have limited treatment options, ORLYNVAH™ provides a long overdue oral alternative that allows for treatment in the community. This paradigm shift in the management of patients with uUTI will not only reduce emergency department visits and hospital admissions, but it will also favorably impact patients' quality of life.' 'Our mission is to create new antibiotics for patients and to be a treatment alternative to address substantial unmet medical needs in the community,' said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. 'For many people with multidrug-resistant uUTIs, options have been exhausted. We're proud to introduce ORLYNVAH™—the first oral penem ever approved by the FDA—giving clinicians and patients a much-needed new therapy.' To support patient access, Iterum Therapeutics is launching a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25. For more information about ORLYNVAH™, including full prescribing information, please visit Uncomplicated urinary tract infections (uUTIs) are a common bladder infection typically confined to the lower urinary tract in otherwise healthy women with no structural abnormalities of the urinary tract—caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. About Iterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit About ORLYNVAH™ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. Cautionary Note Regarding Forward-looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™ and the success of Iterum's commercialization of ORLYNVAH™ in the U.S. In some cases, forward-looking statements can be identified by words such as 'may,' 'believes,' 'intends,' 'seeks,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'should,' 'assumes,' 'continues,' 'could,' 'would,' 'will,' 'future,' 'potential' or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including Iterum's ability to maintain and continue to build a sales force for the commercialization of ORLYNVAH™ in the U.S., the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if the commercialization of ORLYNVAH™ in the U.S. is unsuccessful, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, the potential impact of resistant uUTIs on healthcare costs and medical outcomes for uUTI patients in the U.S., Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PRESS CONTACTJennifer PerciballiOak+Cannon PR for Iterumjennifer@ Investor RelationsJudy MatthewsChief Financial Officer Iterum Therapeutics 312-778-6073IR@
Yahoo
28 minutes ago
- Yahoo
TI Chief Financial Officer Rafael Lizardi to speak at Citi investor conference
Sept. 4, 2025, 8:10 a.m. Eastern time DALLAS, Aug. 20, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Citi 2025 Global TMT Conference in New York City on Thursday, Sept. 4, at 8:10 a.m. Eastern time. Lizardi will field questions from analysts and investors, as well as discuss TI's business outlook and its strategy to address key markets for its analog and embedded processing technologies and how these capabilities position the company for growth. The audio webcast for the conference can be accessed live through the Investor Relations section ( of TI's website. An archived replay will be available on the website after his remarks. About Texas Instruments Texas Instruments Incorporated (Nasdaq: TXN) is a global semiconductor company that designs, manufactures and sells analog and embedded processing chips for markets such as industrial, automotive, personal electronics, enterprise systems and communications equipment. At our core, we have a passion to create a better world by making electronics more affordable through semiconductors. This passion is alive today as each generation of innovation builds upon the last to make our technology more reliable, more affordable and lower power, making it possible for semiconductors to go into electronics everywhere. Learn more at TXN-G View original content to download multimedia: SOURCE Texas Instruments Incorporated
Yahoo
36 minutes ago
- Yahoo
Analog Devices Shares Jump After Blowout Quarter and Upbeat Forecast
This article first appeared on GuruFocus. Aug 20 - Analog Devices (NASDAQ:ADI) gained roughly 4% on Wednesday after reporting fiscal third-quarter results that topped Wall Street expectations and offering stronger-than-expected guidance for the current quarter. The move came even as most other semiconductor stocks traded lower. Warning! GuruFocus has detected 11 Warning Signs with ADI. Revenue in the third quarter rose about 4% above consensus and exceeded the high end of the company's guided range. Communications and Consumer segments delivered notable strength, with sales beating analyst forecasts by 15% and 6%, respectively. Management projected fiscal fourth-quarter revenue to grow 4% sequentially, which is 6% ahead of consensus expectations. Analysts were quick to weigh in. Wells Fargo reiterated an Equal Weight rating with a $235 price target, noting solid bookings and pointing to forward visibility as a key factor for recovery heading into fiscal 2026. Evercore maintained its Outperform rating with a $280 price target, citing the revenue beats and robust demand outlook. Truist kept its Hold rating and $219 price target, highlighting that tariffs and trade fluctuations still cloud the broader market backdrop. With macro uncertainty continuing, investors seem buoyed by the fact that Analog Devices is able to move through the changing environment and still show a high level of demand in the most important markets.
